• Je něco špatně v tomto záznamu ?

Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications

L. Tesarova, K. Jaresova, P. Simara, I. Koutna

. 2020 ; 21 (15) : . [pub] 20200728

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012338

Grantová podpora
CZ.02.1.01/0.0/0.0/16_013/0001826 European Regional Development Fund - project CZECRIN_4 PACIENTY
LQ1605 MEYS CR, NPU II

Mesenchymal stem cells (MSCs) have become a promising tool in cellular therapy for restoring immune system haemostasis; however, the success of clinical trials has been impaired by the lack of standardized manufacturing processes. This study aims to determine the suitability of source tissues and culture media for the production of MSC-based advanced therapy medicinal products (ATMPs) and to define parameters to extend the set of release criteria. MSCs were isolated from umbilical cord (UC), bone marrow and lipoaspirate and expanded in three different culture media. MSC phenotype, proliferation capacity and immunosuppressive parameters were evaluated in normal MSCs compared to primed MSCs treated with cytokines mimicking an inflammatory environment. Compared to bone marrow and lipoaspirate, UC-derived MSCs (UC-MSCs) showed the highest proliferative capacity, which was further enhanced by media supplemented with bFGF, while the cells maintained their immunosuppressive characteristics. Moreover, UC-MSCs expanded in the bFGF-enriched medium were the least sensitive to undesirable priming-induced changes in the MSC phenotype. Surface markers and secreted factors were identified to reflect the cell response to inflammatory priming and to be variable among MSCs from different source tissues. This study demonstrates that UC is a favorable cell source for manufacturing MSC-based ATMPs for immunosuppressive applications. UC-MSCs are able to use the bFGF-enriched medium for higher cell yields without the impairment of immunosuppressive parameters and undesirable phenotype changes after inflammatory preconditioning of MSCs before transplantation. Additionally, immunosuppressive parameters were identified to help finding predictors of clinically efficient MSCs in the following clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012338
003      
CZ-PrNML
005      
20210714100043.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms21155366 $2 doi
035    __
$a (PubMed)32731615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tesarova, Lenka $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
245    10
$a Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications / $c L. Tesarova, K. Jaresova, P. Simara, I. Koutna
520    9_
$a Mesenchymal stem cells (MSCs) have become a promising tool in cellular therapy for restoring immune system haemostasis; however, the success of clinical trials has been impaired by the lack of standardized manufacturing processes. This study aims to determine the suitability of source tissues and culture media for the production of MSC-based advanced therapy medicinal products (ATMPs) and to define parameters to extend the set of release criteria. MSCs were isolated from umbilical cord (UC), bone marrow and lipoaspirate and expanded in three different culture media. MSC phenotype, proliferation capacity and immunosuppressive parameters were evaluated in normal MSCs compared to primed MSCs treated with cytokines mimicking an inflammatory environment. Compared to bone marrow and lipoaspirate, UC-derived MSCs (UC-MSCs) showed the highest proliferative capacity, which was further enhanced by media supplemented with bFGF, while the cells maintained their immunosuppressive characteristics. Moreover, UC-MSCs expanded in the bFGF-enriched medium were the least sensitive to undesirable priming-induced changes in the MSC phenotype. Surface markers and secreted factors were identified to reflect the cell response to inflammatory priming and to be variable among MSCs from different source tissues. This study demonstrates that UC is a favorable cell source for manufacturing MSC-based ATMPs for immunosuppressive applications. UC-MSCs are able to use the bFGF-enriched medium for higher cell yields without the impairment of immunosuppressive parameters and undesirable phenotype changes after inflammatory preconditioning of MSCs before transplantation. Additionally, immunosuppressive parameters were identified to help finding predictors of clinically efficient MSCs in the following clinical trials.
650    _2
$a buněčná diferenciace $x účinky léků $x imunologie $7 D002454
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a fibroblastový růstový faktor 2 $x imunologie $x farmakologie $7 D016222
650    _2
$a lidé $7 D006801
650    12
$a imunosupresivní léčba $7 D007165
650    _2
$a mezenchymální kmenové buňky $x cytologie $x imunologie $7 D059630
650    _2
$a pupečník $x cytologie $x imunologie $7 D014470
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jaresova, Klara $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
700    1_
$a Simara, Pavel $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
700    1_
$a Koutna, Irena $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 15 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32731615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210714100041 $b ABA008
999    __
$a ok $b bmc $g 1650666 $s 1132717
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 15 $e 20200728 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a CZ.02.1.01/0.0/0.0/16_013/0001826 $p European Regional Development Fund - project CZECRIN_4 PACIENTY
GRA    __
$a LQ1605 $p MEYS CR, NPU II
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace